AU2011311482B2 - Methods of treating psoriasis using IL-17 antagonists - Google Patents

Methods of treating psoriasis using IL-17 antagonists Download PDF

Info

Publication number
AU2011311482B2
AU2011311482B2 AU2011311482A AU2011311482A AU2011311482B2 AU 2011311482 B2 AU2011311482 B2 AU 2011311482B2 AU 2011311482 A AU2011311482 A AU 2011311482A AU 2011311482 A AU2011311482 A AU 2011311482A AU 2011311482 B2 AU2011311482 B2 AU 2011311482B2
Authority
AU
Australia
Prior art keywords
antibody
seq
patient
binding molecule
regimen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2011311482A
Other languages
English (en)
Other versions
AU2011311482A1 (en
Inventor
Achim Guettner
Matthias Machacek
Charis Papavassilis
Oliver Sander
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44759699&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2011311482(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2011311482A1 publication Critical patent/AU2011311482A1/en
Application granted granted Critical
Publication of AU2011311482B2 publication Critical patent/AU2011311482B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2011311482A 2010-10-08 2011-10-07 Methods of treating psoriasis using IL-17 antagonists Active AU2011311482B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39138810P 2010-10-08 2010-10-08
US61/391,388 2010-10-08
PCT/EP2011/067522 WO2012045848A1 (en) 2010-10-08 2011-10-07 Methods of treating psoriasis using il-17 antagonists

Publications (2)

Publication Number Publication Date
AU2011311482A1 AU2011311482A1 (en) 2013-04-04
AU2011311482B2 true AU2011311482B2 (en) 2014-05-29

Family

ID=44759699

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011311482A Active AU2011311482B2 (en) 2010-10-08 2011-10-07 Methods of treating psoriasis using IL-17 antagonists

Country Status (28)

Country Link
US (9) US9717791B2 (enExample)
EP (5) EP3299390A1 (enExample)
JP (2) JP5537740B2 (enExample)
KR (3) KR20150018595A (enExample)
CN (2) CN107029234A (enExample)
AU (1) AU2011311482B2 (enExample)
BR (1) BR112013008501A2 (enExample)
CA (1) CA2813900C (enExample)
CL (1) CL2013000930A1 (enExample)
CY (1) CY1119942T1 (enExample)
DK (1) DK2625199T3 (enExample)
ES (1) ES2660770T3 (enExample)
HK (1) HK1247932A1 (enExample)
HR (1) HRP20180301T1 (enExample)
HU (1) HUE038334T2 (enExample)
IL (1) IL225310A (enExample)
LT (1) LT2625199T (enExample)
MA (1) MA34646B1 (enExample)
MX (1) MX356279B (enExample)
NO (1) NO2625199T3 (enExample)
PH (1) PH12013500660B1 (enExample)
PL (1) PL2625199T3 (enExample)
PT (1) PT2625199T (enExample)
RU (2) RU2591083C2 (enExample)
SG (1) SG188979A1 (enExample)
SI (1) SI2625199T1 (enExample)
TW (2) TWI564022B (enExample)
WO (1) WO2012045848A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
EA031209B9 (ru) 2010-01-15 2021-11-19 Кирин-Эмджен, Инк. Фармацевтический состав антитела для лечения воспалительного заболевания и способы его применения
AU2011254557B2 (en) 2010-05-20 2015-09-03 Ablynx Nv Biological materials related to HER3
PT2625199T (pt) 2010-10-08 2018-02-28 Novartis Ag Métodos de tratamento de psoríase usando antagonistas de il-17
BR112013011176A2 (pt) 2010-11-05 2020-09-01 Novartis Ag métodos de tratamento de artrite reumatoide usando antagonistas de il-17
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
AU2012341081B2 (en) * 2011-11-21 2015-06-04 Novartis Ag Methods of treating psoriatic arthritis (PsA) using IL-17 antagonists and PsA response or non- response alleles
EP3689369A1 (en) * 2013-03-15 2020-08-05 Amgen, Inc Methods for treating psoriasis using an anti-il-23 antibody
WO2014143540A1 (en) * 2013-03-15 2014-09-18 Amgen Inc. Methods for treating crohn's disease using an anti-il23 antibody
US10434172B2 (en) 2013-08-15 2019-10-08 Novartis Ag Methods of treating generalized pustular psoriasis (GPP) using IL-17 antagonists
KR101836756B1 (ko) 2013-12-27 2018-03-08 오사카 유니버시티 Il-17a를 표적화하는 백신
RU2577228C2 (ru) * 2014-03-14 2016-03-10 Закрытое Акционерное Общество "Биокад" Анти-il-17-антитела, способ их получения и способ применения
MY184189A (en) * 2014-03-31 2021-03-24 Amgen K A Inc Methods of treating nail and scalp psoriasis
CA2949236C (en) 2014-05-15 2023-06-13 Incube Labs, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
US11548940B2 (en) 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
WO2016031250A1 (en) * 2014-08-26 2016-03-03 Kirin-Amgen, Inc. Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
SMT202400285T1 (it) * 2014-09-10 2024-09-16 Novartis Ag Uso di antagonisti di il-17 per inibire la progressione del danno strutturale in pazienti affetti da artrite psoriasica
AR103172A1 (es) * 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
CA2978431C (en) 2015-03-02 2023-10-24 180 Therapeutics Lp Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist
EP3167892A1 (en) 2015-11-10 2017-05-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for preventing or treating imflammatory bowel diseases
RU2754683C2 (ru) * 2015-10-27 2021-09-06 Юсб Биофарма Срл Способы лечения с использованием анти-il-17a антител
WO2018015880A1 (en) 2016-07-19 2018-01-25 Novartis Ag Methods of treating new-onset plaque type psoriasis using il-17 antagonists
WO2018096467A1 (en) * 2016-11-28 2018-05-31 Novartis Ag Methods of treating acne using interleukin-17 (il-17) antagonists
WO2018158741A1 (en) * 2017-03-03 2018-09-07 Novartis Ag Psoriasis disease modification following long-term treatment with an il-17 antagonist
EP3672988A1 (en) * 2017-08-23 2020-07-01 Eli Lilly and Company Treatment of genital psoriasis
TWI808397B (zh) * 2018-09-11 2023-07-11 美商美國禮來大藥廠 治療牛皮癬之方法
EP4006053A4 (en) 2019-07-30 2022-10-26 Jiangsu Hengrui Medicine Co., Ltd. METHOD OF TREATMENT OF AUTOIMMUNE DISEASE BY IL-17 ANTAGONISTS
BR112022004941A2 (pt) 2019-09-20 2022-06-28 Novartis Ag Métodos para tratar doenças autoimunes com o uso de antagonistas de interleucina-17 (il-17)
WO2022127842A1 (zh) * 2020-12-17 2022-06-23 上海华奥泰生物药业股份有限公司 靶向il-17a和il-36r的双特异性抗体及其应用
TW202246329A (zh) * 2021-03-03 2022-12-01 大陸商蘇州盛迪亞生物醫藥有限公司 抗il-17抗體治療自體免疫性疾病和炎症的方法
WO2023186174A1 (en) * 2022-04-01 2023-10-05 Zai Lab (Shanghai) Co., Ltd. Topical formulation comprising an il-17a binding molecule and uses thereof
CN116593718B (zh) * 2023-07-18 2023-09-15 军科正源（北京）药物研究有限责任公司 用于检测司库奇尤单抗抗药性抗体的试剂

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006013107A1 (en) * 2004-08-05 2006-02-09 Novartis Ag Il-17 antagonistic antibodies

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250442A (en) 1993-04-08 1993-10-05 Orestes Cabezas Method of treating rheumatoid arthritis using tetracycline
US6309636B1 (en) 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
GB9422306D0 (en) * 1994-11-04 1994-12-21 Sandoz Ltd Organic compounds
US6093745A (en) * 1997-11-25 2000-07-25 Psorx, L.L.C. Methods and composition for treating skin proliferative diseases
US20050147609A1 (en) 1998-05-15 2005-07-07 Genentech, Inc. Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis
JP2000186046A (ja) 1998-10-14 2000-07-04 Snow Brand Milk Prod Co Ltd 慢性関節リウマチ治療剤及び診断方法
JP4159682B2 (ja) 1998-12-22 2008-10-01 株式会社クラレ 止血材
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders
US20090280065A1 (en) * 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
US8039642B2 (en) 2003-12-09 2011-10-18 Life Technologies Corporation Pyrenyloxysulfonic acid fluorescent agents
TWI439284B (zh) * 2004-04-09 2014-06-01 Abbvie Biotechnology Ltd 用於治療ＴＮＦα相關失調症之多重可變劑量療法
WO2006096461A2 (en) 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Composition comprising an antibody against macrophage colony-stimulating factor (m-csf) and a chelating agent
EP2322219A3 (en) * 2005-09-01 2013-06-05 Merck Sharp & Dohme Corp. Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
LT2481753T (lt) * 2005-12-13 2018-05-25 Eli Lilly And Company Anti-il-17 antikūnai
RU2430110C2 (ru) 2006-01-31 2011-09-27 Новартис Аг Антитела - антагонисты интерлейкина-17 (ил-17) для лечения рака
TW200815469A (en) 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
EA200970250A1 (ru) 2006-09-05 2010-02-26 Медарекс, Инк. Антитела к костным морфогенетическим белкам и их рецепторам и способы их применения
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
RU2367429C2 (ru) 2007-01-30 2009-09-20 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Способ лечения псориаза
AU2008232903B9 (en) 2007-03-30 2013-09-05 Medimmune Llc Antibodies with decreased deamidation profiles
EP2152318A4 (en) * 2007-06-01 2011-12-07 Abbott Biotech Ltd COMPOSITIONS AND USES FOR THE TREATMENT OF PSORIASIS AND CROHN'S DISEASE
CN101932935A (zh) 2007-06-20 2010-12-29 先灵公司 用于炎性关节病抗白介素-17a治疗的关节破坏生物标记
US7720605B2 (en) 2007-06-22 2010-05-18 Weyerhaeuser Nr Company Identifying vegetation attributes from LiDAR data
RU2341272C1 (ru) * 2007-10-22 2008-12-20 Левон Никитович Мкртчян Средство для неспецифической иммунотерапии
JP2011523853A (ja) 2008-06-03 2011-08-25 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリン及びその使用
US20090301682A1 (en) 2008-06-05 2009-12-10 Baker Hughes Incorporated Casting furnace method and apparatus
BRPI0915448A2 (pt) 2008-07-08 2015-11-10 Abbott Lab imunoglobulinas de domínio variável duplo para prostaglandina e2 e usos das mesmas
KR101318549B1 (ko) * 2008-09-29 2013-10-16 로슈 글리카트 아게 인간 ｉｌ17 에 대한 항체 및 이의 용도
BRPI0921845A2 (pt) 2008-11-12 2019-09-17 Medimmune Llc formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata
US20110256130A1 (en) 2008-12-01 2011-10-20 Joshua Robert Schultz Methods of treating inflammatory disorders
SG173705A1 (en) 2009-03-05 2011-09-29 Abbott Lab Il-17 binding proteins
PT2625199T (pt) 2010-10-08 2018-02-28 Novartis Ag Métodos de tratamento de psoríase usando antagonistas de il-17
BR112013011176A2 (pt) 2010-11-05 2020-09-01 Novartis Ag métodos de tratamento de artrite reumatoide usando antagonistas de il-17
AR084234A1 (es) 2010-12-13 2013-05-02 Novartis Ag Metodos predictivos y metodos para tratar artritis usando antagonistas de interleuquina 17 (il-17)
AU2012341081B2 (en) 2011-11-21 2015-06-04 Novartis Ag Methods of treating psoriatic arthritis (PsA) using IL-17 antagonists and PsA response or non- response alleles
JP2015519311A (ja) 2012-04-20 2015-07-09 ノバルティス アーゲー Ｉｌ−１７アンタゴニストを用いて強直性脊椎炎を治療する方法
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
IL257723B2 (en) 2015-10-19 2023-04-01 Novartis Ag Methods for the treatment of non-radiographic sclerosing spondylitis with the help of interleukin-17 (il-17) antagonists
US11280479B2 (en) 2017-10-18 2022-03-22 The Sloan Company Sign box light module

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006013107A1 (en) * 2004-08-05 2006-02-09 Novartis Ag Il-17 antagonistic antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HUEBER, W. et al., ' Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis', Sci Transl Med. 6 October 2010, Volume. 2, 52ra72 *

Also Published As

Publication number Publication date
JP2014114288A (ja) 2014-06-26
CA2813900C (en) 2017-01-10
PH12013500660A1 (en) 2013-05-20
US12551554B2 (en) 2026-02-17
MX356279B (es) 2018-05-22
KR20130110179A (ko) 2013-10-08
TW201630625A (zh) 2016-09-01
PL2625199T3 (pl) 2018-04-30
PT2625199T (pt) 2018-02-28
SG188979A1 (en) 2013-05-31
RU2591083C2 (ru) 2016-07-10
KR101620771B1 (ko) 2016-05-12
US20250161443A1 (en) 2025-05-22
HK1247932A1 (en) 2018-10-05
CL2013000930A1 (es) 2014-03-28
US20130202610A1 (en) 2013-08-08
NO2625199T3 (enExample) 2018-04-21
US20170304439A1 (en) 2017-10-26
KR20140097566A (ko) 2014-08-06
IL225310A0 (en) 2013-06-27
AU2011311482A1 (en) 2013-04-04
WO2012045848A1 (en) 2012-04-12
MA34646B1 (fr) 2013-11-02
US20200171147A1 (en) 2020-06-04
PH12013500660B1 (en) 2017-10-27
CY1119942T1 (el) 2018-12-12
EP4670788A2 (en) 2025-12-31
US20210162044A1 (en) 2021-06-03
LT2625199T (lt) 2018-03-12
DK2625199T3 (en) 2018-02-26
US9717791B2 (en) 2017-08-01
KR20150018595A (ko) 2015-02-23
IL225310A (en) 2016-10-31
US20210113688A1 (en) 2021-04-22
JP5537740B2 (ja) 2014-07-02
HUE038334T2 (hu) 2018-10-29
BR112013008501A2 (pt) 2016-08-16
MX2013003916A (es) 2013-06-03
JP2013543501A (ja) 2013-12-05
US20250161445A1 (en) 2025-05-22
EP3299390A1 (en) 2018-03-28
US20250161444A1 (en) 2025-05-22
EP4137514A1 (en) 2023-02-22
US20230321231A1 (en) 2023-10-12
EP2625199A1 (en) 2013-08-14
US11534490B2 (en) 2022-12-27
CA2813900A1 (en) 2012-04-12
CN107029234A (zh) 2017-08-11
US10583190B2 (en) 2020-03-10
EP3792281A1 (en) 2021-03-17
EP2625199B1 (en) 2017-11-22
RU2665954C1 (ru) 2018-09-05
TWI564022B (zh) 2017-01-01
TWI548419B (zh) 2016-09-11
CN103154031A (zh) 2013-06-12
RU2013120957A (ru) 2014-11-20
EP4670788A3 (en) 2026-03-18
HRP20180301T1 (hr) 2018-03-23
TW201216984A (en) 2012-05-01
SI2625199T1 (en) 2018-03-30
ES2660770T3 (es) 2018-03-26

Similar Documents

Publication Publication Date Title
US12551554B2 (en) Methods of treating chronic inflammatory disease with secukinumab
US11351253B2 (en) Methods of treating palmoplantar pustular psoriasis (PPP) using IL-17 antibody
US20230321232A1 (en) Methods of treating generalized pustular psoriasis (gpp) using il-17 antagonists
HK40097110A (en) Methods of treating plaque psoriasis using il-17 antagonists
HK40088403A (en) Methods of treating psoriasis using il-17 antagonists
HK40037862A (en) Methods of treating psoriasis using il-17 antagonists
HK1183673A (en) Methods of treating psoriasis using il-17 antagonists
HK1183673B (en) Methods of treating psoriasis using il-17 antagonists

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)